Justus-Liebig-University, Clinic for Urology, Pediatric Urology and Andrology, Universitätsklinikum Giessen und Marburg, Standort Giessen, Giessen, Germany.
Expert Opin Emerg Drugs. 2010 Sep;15(3):375-97. doi: 10.1517/14728214.2010.500613.
Bacterial urinary tract infections (UTIs) are amongst the most common infectious diseases. Therefore, any improvement in UTI management will have a high impact on the quality of life of the individual patient and the entire healthcare system. A dramatic, clinically significant increase in the antimicrobial resistance of uropathogens over the past 5 - 10 years calls for new concepts in the treatment of UTIs.
This article focuses on uncomplicated and complicated UTIs, and discusses antimicrobial resistance trends and antibacterial strategies. A literature search was undertaken concerning treatment studies in UTI from 1998 on. Emerging drugs for the treatment of UTI were mainly selected using the Investigational Drugs Database.
The aim of this review is to highlight new and emerging drugs in the antibacterial treatment of uncomplicated and complicated UTIs. This article discusses current and future aspects for recommending antibacterials for the treatment of UTIs.
Resistance rates of uropathogens are also significantly increasing. Emerging antimicrobial substances are not always investigated for their suitability in the treatment of UTIs. Especially, substances active against multiresistant Gram-negative pathogens will rarely be developed in the coming years.
细菌尿路感染 (UTI) 是最常见的传染病之一。因此，任何对 UTI 管理的改进都将对个体患者和整个医疗保健系统的生活质量产生重大影响。过去 5-10 年，尿路病原体的抗菌耐药性急剧上升，这需要在 UTI 治疗方面提出新概念。
本文重点关注单纯性和复杂性 UTI，并讨论了抗菌耐药趋势和抗菌策略。对 1998 年以来 UTI 治疗研究进行了文献检索。主要使用研究用药物数据库选择用于治疗 UTI 的新兴药物。
本文旨在强调单纯性和复杂性 UTI 抗菌治疗中的新型和新兴药物。本文讨论了目前和未来推荐用于治疗 UTI 的抗菌药物的方面。
尿路病原体的耐药率也在显著上升。新兴抗菌物质并不总是针对其在 UTI 治疗中的适用性进行调查。特别是，在未来几年内，针对多药耐药革兰氏阴性病原体的活性物质很少开发。
